Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors,

Elizabeth Turner1, Victor Dishy, Cecilia P Chung

  • 1Division of Clinical Pharmacology, Center of Health Services Research, Department of Biostatistics, 560 Robinson Research Building, Vanderbilt University School of Medicine, Nashville, TN, 37232-6602, USA.

Insights

Endothelial dysfunction in systemic lupus erythematosus patients is linked to corticosteroid use. This pilot study suggests long-term corticosteroid therapy may impair vascular endothelial function.

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Vascular Biology

Background:

  • Systemic lupus erythematosus (SLE) is associated with increased risk of premature coronary artery disease.
  • Endothelial dysfunction is a common finding in SLE patients and a key contributor to atherosclerosis.
  • Understanding factors influencing endothelial function in SLE is crucial for cardiovascular risk management.

Purpose of the Study:

  • To investigate the relationship between endothelial function and disease activity in lupus patients.
  • To assess the association between cardiovascular risk factors and endothelial function in this population.
  • To explore the impact of specific SLE treatments, like corticosteroids, on endothelial health.

Main Methods:

  • Evaluated 20 lupus patients, assessing clinical characteristics and cardiovascular risk factors.
  • Measured brachial artery flow-mediated dilation using high-resolution ultrasound.
  • Determined coronary calcification via electron-beam computed tomography.

Main Results:

  • Median flow-mediated dilation was 3.6% (1.7%-7.7%).
  • No significant correlation found between endothelial function and disease activity markers or general cardiovascular risk factors.
  • A significant inverse association was observed between flow-mediated dilation and the duration of corticosteroid therapy (RHO = -0.44, p = 0.05).

Conclusions:

  • Endothelial dysfunction in lupus patients may be associated with long-term corticosteroid exposure.
  • These preliminary findings highlight corticosteroids as a potential factor contributing to vascular impairment in SLE.
  • Further research is warranted to confirm these results and elucidate the mechanisms involved.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...